Post-DS Broadcast Survey Question Title * 1. Please provide your email address Question Title * 2. What is your specialty? Neurologist Epileptologist Pediatric neurologist Pediatric epileptologist Nurse practitioner Physician assistant Other: Please specify Question Title * 3. How would you rate your awareness of FINTEPLA as a potential treatment for Dravet syndrome prior to this program? Aware and very familiar with the clinical profile Aware and somewhat familiar with the clinical profile Aware but low familiarity with the clinical profile Unaware Question Title * 4. After the program, how confident are you to initiate a trial of FINTEPLA in appropriate Dravet syndrome patients? Confident Somewhat confident Not very confident Not confident; need more information Question Title * 5. From the following statements, which do you believe is the single most compelling reason to consider FINTEPLA for your Dravet syndrome patients? Profound and sustained reduction in monthly convulsive seizure frequency (MCSF) ≥3 weeks seizure freedom achieved in 50% of patients No adjustment to baseline ASMs No worsening of behavior, emotion, and cognition Question Title * 6. Please share any additional feedback on the program FINTEPLA® is a registered trademark of the UCB Group of Companies. ©2024 UCB, Inc., 1950 Lake Park Drive, Smyrna, GA 30080. All rights reserved. US-FA-2400475 Done